Presentation TCT 2017 Should the Type of Stent Influence DAPT Decisions in Patients Receiving OAC? Insights From WOEST, LEADERS Free, and More Presenter: Robert A. Harrington, Kurt Huber, Didier Carrié November 01, 2017
Presentation TCT 2017 Case #1 (With Discussion): Aortic Stenosis With Concomitant CAD Presenter: William F. Fearon, Matthias Götberg, Gary S. Mintz, Evelyn S. Regar November 01, 2017
News Conference News TCT 2017 Shortened DAPT Durations Appear Safe for Patients With ACS Implanted With DES Todd Neale November 01, 2017
Presentation TCT 2017 What Is (and Is Not) Known About DAPT Decisions in Patients on Chronic Oral Anticoagulants Presenter: Robert A. Harrington, Kurt Huber, Freek W.A. Verheugt November 01, 2017
Presentation TCT 2017 Cooperation Between Italian Society of Interventional Cardiology (GISE) and the Bulgarian Cardiac Institute in Bulgaria: Impressive Reduction in the Mortality of CAD Presenter: Vinay K. Bahl, Alice K. Jacobs, Farhat Fouladvand November 01, 2017
Presentation TCT 2017 Optimizing the Acute and Chronic Use of Antiplatelet and Antithrombotic Agents (and Their Combination): 2017 Update Presenter: Debabrata Mukherjee, E. Murat Tuzcu, Dimitrios Alexopoulos November 01, 2017
Presentation TCT 2017 REDUCE: A Randomized Trial of 3-Month vs 12-Month DAPT After Implantation of a Bioabsorbable Polymer-Based Metallic DES With a Luminal CD34+ Antibody Coating in Patients With ACS Presenter: Robert A. Harrington, Gregg W. Stone, Harry Suryapranata November 01, 2017
News Opinion Editor's Corner TCT 2017 Live From Denver: TCT 2017, Day Three Shelley Wood November 01, 2017
Presentation TCT 2017 DAPT STEMI: A Randomized Trial of 6-Month vs 12-Month DAPT After DES Implantation in STEMI Presenter: Robert A. Harrington, Gregg W. Stone, Elvin Kedhi November 01, 2017
Presentation TCT 2017 SENIOR: A Randomized Trial of a Bioabsorbable Polymer-Based Metallic DES vs a BMS With Short DAPT in Patients With Coronary Artery Disease Older Than 75 Years Presenter: Robert A. Harrington, Gregg W. Stone, Olivier Varenne November 01, 2017
Presentation TCT 2017 What Is the Optimal DAPT Duration With ABSORB? Results From a Comprehensive Meta-Analysis Presenter: Azeem Latib, Gregg W. Stone October 31, 2017
Presentation TCT 2017 FDA Perspectives on Short DAPT IDE Trials Presenter: Mitchell W. Krucoff, P.F. Adrian Magee October 31, 2017
Presentation TCT 2017 The High-Bleeding-Risk Patient: Physician-Scientist Perspectives on Standard vs Novel DES and DAPT Duration Presenter: Mitchell W. Krucoff, P.F. Adrian Magee, Ajay J. Kirtane October 31, 2017
Presentation TCT 2017 The High-Bleeding-Risk Patient: Physician-Scientist Perspectives on Appropriate Patients and DAPT Duration Presenter: Mitchell W. Krucoff, P.F. Adrian Magee, Marie-Claude Morice October 31, 2017
Presentation TCT 2017 Rationale and Studies of P2Y12 Inhibitor Monotherapy Presenter: Dominick J. Angiolillo, Marco Valgimigli, Roxana Mehran October 30, 2017
Presentation TCT 2017 Utility of Genotyping and Platelet Function Testing to Guide Antiplatelet Therapy: 2017 Assessment Presenter: Dominick J. Angiolillo, Marco Valgimigli, Thomas Engstroem October 30, 2017
Presentation TCT 2017 Switching to and From Cangrelor: When and How? Presenter: Dominick J. Angiolillo, Marco Valgimigli October 30, 2017
Presentation TCT 2017 Switching Between Oral P2Y12 Receptor Inhibitors: When and How? Presenter: Dominick J. Angiolillo, Marco Valgimigli, Matthew J. Price October 30, 2017
Presentation TCT 2017 Crushing and Chewing Oral P2Y12 Receptor Inhibitors: Pharmacodynamic and Clinical Impact Presenter: Dominick J. Angiolillo, Marco Valgimigli, Fabiana Rollini October 30, 2017
Presentation TCT 2017 Impact of Race and Sex on Platelet Reactivity and Clinical Implications Presenter: Dominick J. Angiolillo, Marco Valgimigli, Ron Waksman October 30, 2017